HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients

Objective. To investigate the relationship between insulin resistance and viral load decay in nondiabetic and noncirrhotic genotype 1 chronic HCV patients during peginterferon and ribavirin treatment and the possible influence of BMI and leptin as metabolic confounders. Methods. 75 consecutive nonci...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessandro Grasso, Federica Malfatti, Gabriella Andraghetti, Simona Marenco, Chiara Mazzucchelli, Sara Labanca, Renzo Cordera, Roberto Testa, Antonino Picciotto
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2015/975695
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850235051863703552
author Alessandro Grasso
Federica Malfatti
Gabriella Andraghetti
Simona Marenco
Chiara Mazzucchelli
Sara Labanca
Renzo Cordera
Roberto Testa
Antonino Picciotto
author_facet Alessandro Grasso
Federica Malfatti
Gabriella Andraghetti
Simona Marenco
Chiara Mazzucchelli
Sara Labanca
Renzo Cordera
Roberto Testa
Antonino Picciotto
author_sort Alessandro Grasso
collection DOAJ
description Objective. To investigate the relationship between insulin resistance and viral load decay in nondiabetic and noncirrhotic genotype 1 chronic HCV patients during peginterferon and ribavirin treatment and the possible influence of BMI and leptin as metabolic confounders. Methods. 75 consecutive noncirrhotic, nonobese, and nondiabetic patients with genotype 1 chronic hepatitis C treated with peginterferon alpha 2a plus ribavirin were evaluated. HOMA-IR, serum leptin, and BMI were measured in all patients at baseline and at weeks 12 and 48, whereas viral load was measured at the same time points and then 24 weeks after the end of treatment. Results. HOMA-IR was significantly associated with both BMI and leptin at baseline. During peginterferon plus ribavirin treatment, there was a significant reduction of HOMA-IR at weeks 12 and 48 from baseline (P=0.033 and 0.048, resp.) in patients who achieved an early viral load decay (EVR), a trend not observed in patients who not achieved EVR. No variations during treatment were observed regarding BMI and leptin irrespective of EVR. Conclusion. The early reduction of HOMA-IR but not of BMI and leptin during antiviral treatment in noncirrhotic, chronic hepatitis C genotype 1 patients who achieved EVR suggests a viral genesis of insulin resistance in patients with nonmetabolic phenotype.
format Article
id doaj-art-0e2d6036f44a4c3ab7daf0f7872a1e68
institution OA Journals
issn 1687-6121
1687-630X
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-0e2d6036f44a4c3ab7daf0f7872a1e682025-08-20T02:02:25ZengWileyGastroenterology Research and Practice1687-61211687-630X2015-01-01201510.1155/2015/975695975695HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 PatientsAlessandro Grasso0Federica Malfatti1Gabriella Andraghetti2Simona Marenco3Chiara Mazzucchelli4Sara Labanca5Renzo Cordera6Roberto Testa7Antonino Picciotto8Gastroenterology Unit, San Paolo Hospital, Via Genova 38, 17100 Savona, ItalyGastroenterology Unit, San Paolo Hospital, Via Genova 38, 17100 Savona, ItalyDepartment of Endocrinology, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, ItalyGastroenterology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, ItalyDepartment of Endocrinology, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, ItalyGastroenterology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, ItalyDepartment of Endocrinology, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, ItalyGastroenterology Unit, San Paolo Hospital, Via Genova 38, 17100 Savona, ItalyGastroenterology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, ItalyObjective. To investigate the relationship between insulin resistance and viral load decay in nondiabetic and noncirrhotic genotype 1 chronic HCV patients during peginterferon and ribavirin treatment and the possible influence of BMI and leptin as metabolic confounders. Methods. 75 consecutive noncirrhotic, nonobese, and nondiabetic patients with genotype 1 chronic hepatitis C treated with peginterferon alpha 2a plus ribavirin were evaluated. HOMA-IR, serum leptin, and BMI were measured in all patients at baseline and at weeks 12 and 48, whereas viral load was measured at the same time points and then 24 weeks after the end of treatment. Results. HOMA-IR was significantly associated with both BMI and leptin at baseline. During peginterferon plus ribavirin treatment, there was a significant reduction of HOMA-IR at weeks 12 and 48 from baseline (P=0.033 and 0.048, resp.) in patients who achieved an early viral load decay (EVR), a trend not observed in patients who not achieved EVR. No variations during treatment were observed regarding BMI and leptin irrespective of EVR. Conclusion. The early reduction of HOMA-IR but not of BMI and leptin during antiviral treatment in noncirrhotic, chronic hepatitis C genotype 1 patients who achieved EVR suggests a viral genesis of insulin resistance in patients with nonmetabolic phenotype.http://dx.doi.org/10.1155/2015/975695
spellingShingle Alessandro Grasso
Federica Malfatti
Gabriella Andraghetti
Simona Marenco
Chiara Mazzucchelli
Sara Labanca
Renzo Cordera
Roberto Testa
Antonino Picciotto
HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients
Gastroenterology Research and Practice
title HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients
title_full HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients
title_fullStr HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients
title_full_unstemmed HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients
title_short HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients
title_sort homa bmi and serum leptin levels variations during antiviral treatment suggest virus related insulin resistance in noncirrhotic nonobese and nondiabetic chronic hepatitis c genotype 1 patients
url http://dx.doi.org/10.1155/2015/975695
work_keys_str_mv AT alessandrograsso homabmiandserumleptinlevelsvariationsduringantiviraltreatmentsuggestvirusrelatedinsulinresistanceinnoncirrhoticnonobeseandnondiabeticchronichepatitiscgenotype1patients
AT federicamalfatti homabmiandserumleptinlevelsvariationsduringantiviraltreatmentsuggestvirusrelatedinsulinresistanceinnoncirrhoticnonobeseandnondiabeticchronichepatitiscgenotype1patients
AT gabriellaandraghetti homabmiandserumleptinlevelsvariationsduringantiviraltreatmentsuggestvirusrelatedinsulinresistanceinnoncirrhoticnonobeseandnondiabeticchronichepatitiscgenotype1patients
AT simonamarenco homabmiandserumleptinlevelsvariationsduringantiviraltreatmentsuggestvirusrelatedinsulinresistanceinnoncirrhoticnonobeseandnondiabeticchronichepatitiscgenotype1patients
AT chiaramazzucchelli homabmiandserumleptinlevelsvariationsduringantiviraltreatmentsuggestvirusrelatedinsulinresistanceinnoncirrhoticnonobeseandnondiabeticchronichepatitiscgenotype1patients
AT saralabanca homabmiandserumleptinlevelsvariationsduringantiviraltreatmentsuggestvirusrelatedinsulinresistanceinnoncirrhoticnonobeseandnondiabeticchronichepatitiscgenotype1patients
AT renzocordera homabmiandserumleptinlevelsvariationsduringantiviraltreatmentsuggestvirusrelatedinsulinresistanceinnoncirrhoticnonobeseandnondiabeticchronichepatitiscgenotype1patients
AT robertotesta homabmiandserumleptinlevelsvariationsduringantiviraltreatmentsuggestvirusrelatedinsulinresistanceinnoncirrhoticnonobeseandnondiabeticchronichepatitiscgenotype1patients
AT antoninopicciotto homabmiandserumleptinlevelsvariationsduringantiviraltreatmentsuggestvirusrelatedinsulinresistanceinnoncirrhoticnonobeseandnondiabeticchronichepatitiscgenotype1patients